Agri Articles
(e-Magazine for Agricultural Articles)
Volume: 04, Issue: 03 (MAY-JUNE, 2024)
Available online at http://www.agriarticles.com

Genetic Polymorphism: Driving Precision Medicine in Clinical Practice

(*Ravi Prakash G[1], Haritha Pala[2], Abhilash S[3], Subhashree Parida[1] and Thakur Uttam Singh[1])
[1]Division of Pharmacology & Toxicology, ICAR-IVRI, Bareilly
[2]Division of Animal genetics & Breeding, ICAR-NDRI, Karnal
[3]Department of Veterinary Microbiology, ICAR-IVRI, Bareilly
*Corresponding Author's email: rprakash376.rp@gmail.com

Gene polymorphism refers to the occurrence of two or more different alleles at a gene locus within a population, where the least common allele has a frequency of at least 1% [1]. This genetic variability is a key driver of diversity within and between species and has significant implications for evolution, medicine, and personalized therapy [2, 3]. Gene polymorphism encompasses various types of genetic variations, including Single Nucleotide Polymorphisms (SNPs), which involve a single base change in the DNA sequence, such as a switch from adenine (A) to guanine (G). Insertion/Deletion Polymorphisms (Indels) refer to the addition or loss of small DNA segments within a gene, like a few nucleotides being inserted or deleted. Copy Number Variations (CNVs) involve differences in the number of copies of a particular gene or DNA segment, with some individuals having multiple copies of a gene while others have only one. Lastly, Microsatellites or Short Tandem Repeats (STRs) are repeating sequences of 2-6 base pairs of DNA, exemplified by a sequence like "AGAT" repeated multiple times in succession [4].

Examples of gene polymorphisms in medicine include variations in the CYP450 enzyme family, such as CYP2D6, CYP2C9, and CYP3A5, which influence how drugs are metabolized, affecting their effectiveness and potential toxicity [5]. The Human Leukocyte Antigen (HLA) system is another example, being highly polymorphic and crucial for immune function, with HLA typing being vital for ensuring compatibility in organ transplants [6]. Polymorphisms in the MTHFR gene can alter folate metabolism and are linked to cardiovascular diseases and certain cancers [7]. Moreover, variations in the APOE gene are connected to Alzheimer's disease risk, particularly the APOE ε4 allele, which is associated with a higher likelihood of late-onset Alzheimer's [8]

In pharmacology, genetic polymorphism primarily manifests in two types: pharmacokinetic and pharmacodynamic. Pharmacokinetic genetic polymorphism refers to genetic variations that affect how drugs are absorbed, distributed, metabolized, and excreted. Key enzymes affected includes, cytochrome P450 enzymes (CYP2D6, CYP2C9, CYP3A4), UDP-glucuronosyltransferases (UGTs), N-acetyltransferases (NATs), and transport proteins (P-glycoprotein, OATPs). For example, CYP2D6 polymorphisms categorize individuals into different metabolizer types, influencing drug metabolism and response. Clinical implications include the need for personalized dosing to optimize therapeutic outcomes and minimize adverse effects, such as adjusting warfarin dosing based on CYP2C9 and VKORC1 polymorphisms.

Pharmacodynamic genetic polymorphism involves genetic variations that affect drug interactions with biological targets like receptors, enzymes, or ion channels. For instance, beta-adrenergic receptor polymorphisms affect beta-blocker efficacy, while serotonin receptor variations impact antidepressant effectiveness. Genetic differences in VKORC1 and

ACE influence responses to warfarin and ACE inhibitors, respectively, and ion channel gene polymorphisms modify responses to antiarrhythmic drugs.

Role of Genetic Polymorphism in Individual Therapy

Genetic polymorphism plays a significant role in individual therapy, particularly in the field of personalized medicine. By understanding the genetic variations among individuals, healthcare providers can tailor treatments to achieve better outcomes. Here are some key aspects of how genetic polymorphism is used in individual therapy:

1. Pharmacogenomics: Genetic polymorphisms in drug metabolism, efficacy, and adverse reactions are pivotal in personalized medicine. Polymorphisms in genes encoding drug-metabolizing enzymes, such as CYP450 enzymes, determine how individuals metabolize medications, influencing whether they are poor, intermediate, extensive, or ultra-rapid metabolizers of specific drugs [9]. Variations in the VKORC1 gene can impact the efficacy of drugs like warfarin, affecting the dosage needed to achieve therapeutic effects [10]. Additionally, genetic polymorphisms such as HLA-B*5701 can predispose individuals to adverse drug reactions, such as hypersensitivity reactions to medications like abacavir [11]. Understanding these genetic variations allows healthcare providers to personalize treatment strategies, optimizing drug effectiveness, minimizing adverse effects, and improving overall patient care in clinical settings.

2. Targeted Therapies: Genetic polymorphisms in cancer treatment play a pivotal role in advancing precision oncology. Tumor-specific mutations, such as those in the EGFR gene in non-small cell lung cancer, can predict responsiveness to targeted therapies like gefitinib and erlotinib [12]. Precision oncology further utilizes tumor profiling to identify specific genetic alterations that guide the selection of therapies tailored to individual patients. For instance, drugs targeting BRAF mutations in melanoma or HER2 amplification in breast cancer represent effective strategies to inhibit specific molecular pathways driving tumor growth [13]. By leveraging genetic information, clinicians can customize treatment plans, improving therapeutic outcomes while minimizing unnecessary treatments and adverse effects.

3. Predictive Medicine: Disease Risk Assessment: Genetic polymorphisms can be used to assess the risk of developing certain diseases. For instance, BRCA1 and BRCA2 mutations significantly increase the risk of breast and ovarian cancers [14].

4. Gene Therapy: Gene therapy represents a cutting-edge approach aimed at correcting genetic defects directly at the molecular level. By understanding specific genetic polymorphisms, researchers can design more targeted and effective gene therapies. This precision allows for the development of customized treatments tailored to individual genetic profiles, thereby enhancing both the efficacy and safety of therapeutic interventions. Whether addressing inherited disorders or acquired genetic mutations, gene therapy holds promise in transforming the treatment landscape by offering potentially curative options where conventional treatments fall short. As research advances and our understanding of genetic polymorphisms deepens, the potential for personalized gene therapies to become a cornerstone of medical practice continues to grow, promising hope for patients with diverse genetic conditions.

5. Dosage Adjustments: Personalized Dosing: Genetic polymorphisms can inform dosage adjustments for medications. For example, TPMT polymorphisms affect thiopurine metabolism, guiding dose adjustments in patients receiving thiopurine drugs for leukemia or autoimmune diseases [15].

6. Biomarkers: Identification of Biomarkers: Genetic polymorphisms can serve as biomarkers for disease prognosis, treatment response, and drug toxicity. These biomarkers help in making informed clinical decisions [16].

7.Nutrigenomics: Dietary Recommendations: Genetic variations can influence individual responses to nutrients and dietary components. Nutrigenomics uses this information to provide personalized dietary recommendations for health optimization [17].

Practical Applications

Genetic polymorphisms play a critical role in advancing personalized medicine across various medical contexts. In the case of warfarin dosing, genetic variations in CYP2C9 and VKORC1 significantly impact the metabolism and sensitivity to this anticoagulant. Genotyping these polymorphisms allows clinicians to tailor the initial dosage, minimizing the risk of bleeding or clotting complications associated with warfarin therapy [18]. In breast cancer treatment, genetic testing for HER2 gene amplification informs the use of targeted therapies such as trastuzumab in HER2-positive patients, optimizing treatment efficacy [19]. Moreover, the integration of pharmacogenomic testing panels into clinical practice enables comprehensive analysis of multiple genetic polymorphisms to guide medication selection and dosing across a spectrum of conditions including depression, cardiovascular diseases, and cancer [20]. This approach not only enhances treatment outcomes by matching therapies to individual genetic profiles but also underscores the transformative potential of genetic insights in improving patient care and therapeutic precision.

Conclusion

Incorporating genetic polymorphism into individual therapy significantly enhances the precision, efficacy, and safety of medical treatments. By understanding and utilizing genetic variations, healthcare providers can tailor treatments to an individual's genetic profile, optimizing therapeutic outcomes and minimizing adverse effects. This approach, known as personalized medicine, encompasses a range of applications including pharmacogenomics, targeted therapies, predictive medicine, gene therapy, and dosage adjustments. As genetic testing becomes more integrated into clinical practice, the ability to identify and act on genetic polymorphisms will continue to improve patient care, ultimately leading to better health outcomes and a reduction in treatment-related complications.

References

1. Sukhumsirichart, W., Polymorphisms, in Genetic diversity and disease susceptibility. 2018, IntechOpen.
2. Hughes, A.R., et al., Ecological consequences of genetic diversity. 2008. **11**(6): p. 609-623.
3. Lu, Y.-F., et al., Personalized medicine and human genetic diversity. 2014. **4**(9): p. a008581.
4. Al-Koofee, D.A. and S.M.J.T.R.T.i.G.P. Mubarak, Genetic polymorphisms. 2019: p. 1-10.
5. Ingelman-Sundberg, M., et al., Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. 2007. **116**(3): p. 496-526.
6. Mosaad, Y.J.S.j.o.i., Clinical role of human leukocyte antigen in health and disease. 2015. **82**(4): p. 283-306.
7. Liew, S.-C. and E.D.J.E.j.o.m.g. Gupta, Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases. 2015. **58**(1): p. 1-10.
8. van der Flier, W.M., et al., Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ε4 allele. 2011. **10**(3): p. 280-288.
9. Taylor, C., et al., A Review of the Important Role of CYP2D6 in Pharmacogenomics. 2020. **11**(11): p. 1295.

10. D'Andrea, G., et al., A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. 2005. **105**(2): p. 645-649.
11. Hughes, A.R., et al., Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. 2022.
12. Gazdar, A.J.O., Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. 2009. **28**(1): p. S24-S31.
13. Li, W., et al., Combined therapy of dabrafenib and an anti-HER2 antibody–drug conjugate for advanced BRAF-mutant melanoma. 2024. **29**(1): p. 50.
14. King, M.-C., J.H. Marks, and J.B.J.S. Mandell, Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. 2003. **302**(5645): p. 643-646.
15. Teml, A., et al., Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. 2007. **46**: p. 187-208.
16. Rodríguez-Antona, C. and M.J.J.o.i.m. Taron, Pharmacogenomic biomarkers for personalized cancer treatment. 2015. **277**(2): p. 201-217.
17. Stover, P.J.J.T.A.j.o.c.n., Influence of human genetic variation on nutritional requirements. 2006. **83**(2): p. 436S-442S.
18. Belozerceva, L.A., et al., Personalized approach of medication by indirect anticoagulants tailored to the patient—Russian context: what are the prospects? 2012. **3**: p. 1-13.
19. Wang, J., B.J.S.t. Xu, and t. therapy, Targeted therapeutic options and future perspectives for HER2-positive breast cancer. 2019. **4**(1): p. 34.
20. Hippman, C. and C.J.J.o.p.m. Nislow, Pharmacogenomic testing: clinical evidence and implementation challenges. 2019. **9**(3): p. 40.